Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 5/20 | 0.37 |
| ▸ | HTR2A | P28223 | 4/20 | 0.37 |
| ▸ | HTR7 | P34969 | 4/20 | 0.37 |
| ▸ | HTR6 | P50406 | 4/20 | 0.37 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640794 | 0.92 | OPRL1 (0.47) | BACE1OPRL1OPRM1OPRK1MAPK14 | |
| SCHEMBL13640883 | 0.91 | OPRL1 (0.47) | BACE1OPRL1OPRM1OPRK1MAPK14 | |
| SCHEMBL13641004 | 0.84 | AVPR1A (0.35) | BACE1OPRL1OPRM1SETD2HRH3 | |
| SCHEMBL13640964 | 0.83 | OPRM1 (0.48) | BACE1OPRL1OPRM1OPRK1CALCRL | |
| SCHEMBL12084666 | 0.83 | BACE1 (0.47) | BACE1OPRL1OPRM1OPRK1CALCRL | |
| SCHEMBL13640751 | 0.83 | OPRL1 (0.46) | BACE1OPRL1OPRM1OPRK1CALCRL | |
| SCHEMBL12084694 | 0.83 | BACE1 (0.47) | BACE1OPRL1OPRM1OPRK1CALCRL | |
| SCHEMBL13643891 | 0.81 | BACE1 (0.42) | BACE1OPRL1OPRM1OPRK1CALCRL | |
| SCHEMBL13640812 | 0.81 | OPRL1 (0.46) | BACE1OPRL1OPRM1OPRK1CALCRL | |
| SCHEMBL13641011 | 0.80 | SIGMAR1 (0.47) | OPRL1OPRM1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | BACE1 3797/4885OPRL1 108/4885OPRM1 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.